tetano
Editor, Senior Moderator
Vaccine
. 2024 Apr 17:S0264-410X(24)00465-1.
doi: 10.1016/j.vaccine.2024.04.040. Online ahead of print. Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations
Simon van der Pol[SUP] 1 [/SUP], Florian Zeevat[SUP] 2 [/SUP], Maarten J Postma[SUP] 3 [/SUP], Cornelis Boersma[SUP] 4 [/SUP]
Affiliations
Objectives: We assess the cost-effectiveness of switching from standard-dose quadrivalent influenza vaccination (SD-QIV) to high-dose vaccination (HD-QIV) for Dutch adults aged 60 years and older.
Methods: A health-economic model was used to compare the scenario where HD-QIV was implemented compared to the current standard, SD-QIV. This model used a lifetime horizon and assessed the cost-effectiveness from a societal perspective. A recently published meta-analysis was used to incorporate the benefits of HD-QIV, including cardiorespiratory hospitalizations, in analyses considering RCT only or combining RCT and RWE estimates in a scenario analysis.
Results: Implementing HD-QIV is cost effective at its list price, with an ICER of €5,400 per QALY gained. The main driver of these results is the prevention of cardiorespiratory hospitalizations. Other public health benefits are the prevention of GP consults and deaths. HD-QIV is highly likely to be cost-effective, reaching a 100% probability of being cost effective at the Dutch willingness-to-pay threshold of €20,000 per QALY.
Conclusions: Implementing HD-QIV for adults aged 60 and over within the existing influenza vaccination campaign is highly cost effective. HD-QIV may support alleviating potential capacity issues in Dutch hospitals in the winter respiratory season.
Keywords: Cardiorespiratory hospitalizations; Cost-effectiveness analysis; High-dose; Influenza; Quadrivalent.
. 2024 Apr 17:S0264-410X(24)00465-1.
doi: 10.1016/j.vaccine.2024.04.040. Online ahead of print. Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations
Simon van der Pol[SUP] 1 [/SUP], Florian Zeevat[SUP] 2 [/SUP], Maarten J Postma[SUP] 3 [/SUP], Cornelis Boersma[SUP] 4 [/SUP]
Affiliations
- PMID: 38631948
- DOI: 10.1016/j.vaccine.2024.04.040
Objectives: We assess the cost-effectiveness of switching from standard-dose quadrivalent influenza vaccination (SD-QIV) to high-dose vaccination (HD-QIV) for Dutch adults aged 60 years and older.
Methods: A health-economic model was used to compare the scenario where HD-QIV was implemented compared to the current standard, SD-QIV. This model used a lifetime horizon and assessed the cost-effectiveness from a societal perspective. A recently published meta-analysis was used to incorporate the benefits of HD-QIV, including cardiorespiratory hospitalizations, in analyses considering RCT only or combining RCT and RWE estimates in a scenario analysis.
Results: Implementing HD-QIV is cost effective at its list price, with an ICER of €5,400 per QALY gained. The main driver of these results is the prevention of cardiorespiratory hospitalizations. Other public health benefits are the prevention of GP consults and deaths. HD-QIV is highly likely to be cost-effective, reaching a 100% probability of being cost effective at the Dutch willingness-to-pay threshold of €20,000 per QALY.
Conclusions: Implementing HD-QIV for adults aged 60 and over within the existing influenza vaccination campaign is highly cost effective. HD-QIV may support alleviating potential capacity issues in Dutch hospitals in the winter respiratory season.
Keywords: Cardiorespiratory hospitalizations; Cost-effectiveness analysis; High-dose; Influenza; Quadrivalent.